Roche has revealed good results from a phase 2 trial of its oral BTK drug fenebrutinib in relapsing multiple sclerosis as it waits for phase 3 data.

Roche’s move into digital pathology has been lifted by FDA approval of its digital pathology toolkit as an aid to clinical diagnosis.

Get Roche Holding AG (ROG.S) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments ...